Dual Immunization Against RSV With RSVpreF and Nirsevimab

This cohort study aimed to describe RSV-associated lower respiratory tract infection hospitalizations among infants in France who received both maternal RSV-preF vaccination and nirsevimab during the 2024-2025 RSV season.

Corresponding Author: Ludovic Tréluyer, MD, PhD, French National Agency for Medicines and Health Products Safety and French National Health Insurance, 143/147 Boulevard Anatole France, 93285 Saint-Denis Cedex, France (ludovic.treluyer@ansm.sante.fr).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.